These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of nausea nad vomiting in palliative medicine]. Bausewein C Z Arztl Fortbild Qualitatssich; 2000 Sep; 94(7):569-73. PubMed ID: 11048341 [TBL] [Abstract][Full Text] [Related]
4. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [TBL] [Abstract][Full Text] [Related]
5. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Herrstedt J Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455 [TBL] [Abstract][Full Text] [Related]
6. Comparative activity of antiemetic drugs. Jordan K; Schmoll HJ; Aapro MS Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005 [TBL] [Abstract][Full Text] [Related]
7. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Trigg ME; Inverso DM Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391 [TBL] [Abstract][Full Text] [Related]
8. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1143-5. PubMed ID: 16632163 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and cost effectiveness of new antiemetic guidelines. Engstrom C; Hernandez I; Haywood J; Lilenbaum R Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877 [TBL] [Abstract][Full Text] [Related]
11. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Mahesh R; Perumal RV; Pandi PV Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895 [TBL] [Abstract][Full Text] [Related]
12. Granisetron: an update on its clinical use in the management of nausea and vomiting. Aapro M Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811 [TBL] [Abstract][Full Text] [Related]
16. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Goodman M Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378 [TBL] [Abstract][Full Text] [Related]
17. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Mystakidou K; Befon S; Liossi C; Vlachos L Cancer; 1998 Sep; 83(6):1214-23. PubMed ID: 9740088 [TBL] [Abstract][Full Text] [Related]
19. [The neurochemical mechanisms and pharmacological routes to eliminate vomiting in seasickness]. Naletov SV; Beletskiĭ EA Voen Med Zh; 1998 Sep; 319(9):74-6. PubMed ID: 9817022 [No Abstract] [Full Text] [Related]
20. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? de Wit R; Aapro M; Blower PR Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]